Docetaxel: New Indication for Prostate Cancer - A Few More Weeks
February 2006
in “
PubMed
”
TLDR Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
Docetaxel was approved in Europe for treating hormone-resistant metastatic prostate cancer, showing a modest survival benefit. In a study with 1,006 patients, docetaxel combined with prednisone extended median survival by about 2.5 months compared to mitoxantrone-prednisone. Another study with 674 patients found docetaxel with estramustine more effective than mitoxantrone-prednisone, extending survival by 1.9 months. However, docetaxel's adverse effects, including hair loss and severe reactions in 25% of patients, and its high cost, limited its practical benefit. Despite these drawbacks, it was the first cytotoxic agent to prolong survival in this patient group.
